Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progress.

Chow M, Cao M.

Nat Sci Sleep. 2016 Mar 14;8:81-6. doi: 10.2147/NSS.S76711. eCollection 2016. Review.

2.

Challenges in the development of therapeutics for narcolepsy.

Black SW, Yamanaka A, Kilduff TS.

Prog Neurobiol. 2017 May;152:89-113. doi: 10.1016/j.pneurobio.2015.12.002. Epub 2015 Dec 23. Review.

PMID:
26721620
3.

History of narcolepsy at Stanford University.

Mignot EJ.

Immunol Res. 2014 May;58(2-3):315-39. doi: 10.1007/s12026-014-8513-4. Review. Erratum in: Immunol Res. 2015 Jun;62(2):253.

4.

Coreleased orexin and glutamate evoke nonredundant spike outputs and computations in histamine neurons.

Schöne C, Apergis-Schoute J, Sakurai T, Adamantidis A, Burdakov D.

Cell Rep. 2014 May 8;7(3):697-704. doi: 10.1016/j.celrep.2014.03.055. Epub 2014 Apr 24.

5.

Orexin neurons suppress narcolepsy via 2 distinct efferent pathways.

Hasegawa E, Yanagisawa M, Sakurai T, Mieda M.

J Clin Invest. 2014 Feb;124(2):604-16. doi: 10.1172/JCI71017. Epub 2014 Jan 2.

6.

Distinct effects of IPSU and suvorexant on mouse sleep architecture.

Hoyer D, Dürst T, Fendt M, Jacobson LH, Betschart C, Hintermann S, Behnke D, Cotesta S, Laue G, Ofner S, Legangneux E, Gee CE.

Front Neurosci. 2013 Dec 10;7:235. doi: 10.3389/fnins.2013.00235. eCollection 2013.

7.

Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.

Black SW, Morairty SR, Fisher SP, Chen TM, Warrier DR, Kilduff TS.

Sleep. 2013 Mar 1;36(3):325-36. doi: 10.5665/sleep.2442.

8.

Animal models of narcolepsy.

Chen L, Brown RE, McKenna JT, McCarley RW.

CNS Neurol Disord Drug Targets. 2009 Aug;8(4):296-308.

9.

Hypocretin/orexin and narcolepsy: new basic and clinical insights.

Nishino S, Okuro M, Kotorii N, Anegawa E, Ishimaru Y, Matsumura M, Kanbayashi T.

Acta Physiol (Oxf). 2010 Mar;198(3):209-22. doi: 10.1111/j.1748-1716.2009.02012.x. Epub 2009 Jun 25. Review.

10.

Specificity of direct transition from wake to REM sleep in orexin/ataxin-3 transgenic narcoleptic mice.

Fujiki N, Cheng T, Yoshino F, Nishino S.

Exp Neurol. 2009 May;217(1):46-54. doi: 10.1016/j.expneurol.2009.01.015. Epub 2009 Feb 3.

11.

Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls.

Nishino S, Sakurai E, Nevsimalova S, Yoshida Y, Watanabe T, Yanai K, Mignot E.

Sleep. 2009 Feb;32(2):175-80.

12.

Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy.

Mishima K, Fujiki N, Yoshida Y, Sakurai T, Honda M, Mignot E, Nishino S.

Sleep. 2008 Aug;31(8):1119-26.

13.

Narcolepsy: immunological aspects.

Overeem S, Black JL 3rd, Lammers GJ.

Sleep Med Rev. 2008 Apr;12(2):95-107. doi: 10.1016/j.smrv.2007.07.010. Epub 2008 Mar 4. Review.

14.

Characterization of sleep in zebrafish and insomnia in hypocretin receptor mutants.

Yokogawa T, Marin W, Faraco J, Pézeron G, Appelbaum L, Zhang J, Rosa F, Mourrain P, Mignot E.

PLoS Biol. 2007 Oct 16;5(10):e277.

15.

Clinical and neurobiological aspects of narcolepsy.

Nishino S.

Sleep Med. 2007 Jun;8(4):373-99. Epub 2007 Apr 30. Review.

16.

Developmental changes in CSF hypocretin-1 (orexin-A) levels in normal and genetically narcoleptic Doberman pinschers.

John J, Wu MF, Maidment NT, Lam HA, Boehmer LN, Patton M, Siegel JM.

J Physiol. 2004 Oct 15;560(Pt 2):587-92. Epub 2004 Aug 12.

Supplemental Content

Support Center